Cell Therapy · global
Autologous T Cells Followed by NK Cells: South Korea Approves Clinical Research Plan for End-Stage Colorectal Cancer
Seeking a next step for patients whose standard treatments have failed, South Korea will explore sequential infusions of two types of autologous immune cells. The research plan has passed review, but its safety and ability to control cancer still await human data.
When standard treatments such as surgery and targeted cancer therapy fail to control the disease, patients with end-stage colorectal cancer need an evidence-based next step. A clinical research plan in South Korea recently passed review. It proposes isolating immune cells from patients’ own blood, culturing them, and infusing them sequentially to explore whether this approach can delay disease progression in people with limited treatment options.
South Korea’s Ministry of Health and Welfare announced on October 23 that the 11th meeting of the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee in 2026, held the previous day, reviewed three clinical research implementation plans. One was deemed suitable, while two did not pass. The approved study targets patients with end-stage colorectal cancer whose standard treatments have failed and whose disease has metastasized or recurred. Yonhap News Agency and Financial News also reported the decision.
The study uses two types of cells from the patients themselves: T lymphocytes and natural killer cells (NK cells). According to the official explanation, the former can help attack cancer cells and regulate immune responses, while the latter are part of the innate immune system and can recognize and destroy abnormal cells. The research team plans to isolate and culture the cells, then administer them to patients sequentially in separate infusions to examine how this regimen performs in humans.
Efficacy assessments will include the disease control rate and progression-free survival. The disease control rate concerns the proportion of patients whose tumors shrink or remain stable; progression-free survival measures the time during which the disease does not worsen. These measures can help determine whether there are signs of anticancer activity, but no results are currently available to indicate the magnitude of any effect, and they cannot support a claim that the treatment prolongs life.
Safety is also central to the study. News1 reported that the research will assess adverse reactions, clearly distinguishing approval of the plan from proof of efficacy. Officials classified the study as “medium risk,” corresponding to the research category involving patients’ own cultured cells. This classification does not mean that safety following infusion has been established, nor does it constitute marketing authorization for the therapy.
The current announcement and the reports provided do not specify enrollment numbers, doses, the control design, or the date of the first administration. It is therefore not yet possible to determine when the study might generate enough data to support further development. For patients, this decision opens a path to clinical validation. Whether the approach can become a new treatment option still depends on the disease control actually observed and the risks patients must bear.